Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 10/20 | 0.32 |
| ▸ | DPP4 | P27487 | 4/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19937543 | 0.81 | MAPT (0.39) | USP2SMN1; SMN2DPP4GAA | |
| SCHEMBL19937463 | 0.73 | DPP4 (0.38) | SMN1; SMN2ACACBDPP4JAK3GAA | |
| SCHEMBL19937334 | 0.72 | DPP4 (0.44) | DPP4 | |
| SCHEMBL19937456 | 0.70 | KDM4E (0.32) | GAA | |
| SCHEMBL20036692 | 0.70 | NPC1 (0.47) | USP2SMN1; SMN2PDK2DPP4GAA | |
| SCHEMBL14023963 | 0.69 | DPP4 (0.37) | ACACBDPP4 | |
| SCHEMBL15628549 | 0.69 | DPP4 (0.35) | ACACBDPP4 | |
| SCHEMBL15628606 | 0.69 | DPP4 (0.35) | ACACBDPP4 | |
| SCHEMBL16330372 | 0.69 | MAPT (0.50) | USP2SMN1; SMN2PDK2JAK3GAA | |
| SCHEMBL19937527 | 0.69 | ESR1 (0.41) | USP2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3290427-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | Melinta Therapeutics, Inc. (US) | 2018-03-07 | — | — | EP | disclosed |